- Scrip Originals
Brought to you by
Zeria gets Japanese rights to Vifor's hyperkalemia drug
27 Mar 2018
Vifor Pharma Group licensed Zeria Pharmaceutical Co. Ltd. exclusive rights to develop and commercialize the hyperkalemia therapy Veltassa (patiromer) in Japan.
- Marketing (Licensing)
Already a Biomedtracker subscriber? You have access to the full deal record through your subscription
Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com